Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Congress 2021 - 1000x250

Media registration

ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the  ESMO Media Policy which applies to all ESMO events.

To apply for media accreditation, please fill out the form available here:

Complete the Media Registration Form

Media registration in advance is strongly recommended. Further information for press representatives will be made available closer to the event.

Opening press conference

The ESMO2021 Opening Press Conference will be held via Zoom on Thursday, 9 September, 14:00-14:45 CEST.

Moderator:
  • Antonio Passaro, IEO - Istituto Europeo di Oncologia, Italy – ESMO2021 Press Officer
Panellists:
  • Solange Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Switzerland – ESMO President
  • Pasi Jänne, Dana Farner, USA - ESMO2021 Scientific Co-Chair
  • Manola Bettio, European Commission – Joint Research Centre, Ispra, Italy (abstract 1501O_PR)
  • Alessio Cortellini, University of l’Aquila, Italy – (abstract 1560O_PR)

To participate in the Opening Press Conference, media representatives must be accredited for the Congress, prior to Monday 6 September.

Publication schedule for accepted abstracts

Abstracts

Release on ESMO website

Abstracts accepted as:

  • Poster (suffix ‘P’)
  • Poster (suffix ‘TiP’)
  • EONS Poster (prefix ‘CN’)

Monday, 13 September 2021
00:05 CEST (Central European Summer Time)

Abstracts and late-breaking abstracts accepted as:

  • Proffered Paper (suffix ‘O’) selected for presentation in sessions scheduled on 17.09.2021
  • Mini Oral (suffix ‘MO’)

Friday, 17 September 2021
00:05 CEST

Abstracts and late-breaking abstracts accepted as:

  • Proffered Paper (suffix ‘O’)
  • EONS Proffered Paper (prefix ‘CN’)

Saturday, 18 September 2021
00:05 CEST

Abstracts and late-breaking abstracts with a different release schedule or with suffix _PR

See below paragraphs for details

Embargo policy

Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above.

Data and information beyond what is included in all accepted abstracts, for example full data sets, may only be made public at the start of the official programme session during which the study is presented.

Important Note: For the abstracts and late-breaking abstracts listed in the two below paragraphs, changes in embargo rules may apply (see details).

Abstracts selected for press releases (suffix _PR)

Abstract ID

Title

Embargo lift

1501O_PR

Long-term estimates of cancer incidence and mortality for the EU and EFTA countries according to different demographic scenarios

Abstract + full data set: Thursday, 9 September 2021, 14:00 CEST

1560O_PR

Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-Cov-2 infection

Abstract + full data set: Thursday, 9 September 2021, 14:00 CEST

1489P_PR

Tunisian children and adolescents coping with parental cancer.

Abstract: Monday, 13 September 2021, 00:05 CEST

Full data set: Thursday, 16 September 2021, 08:30 CEST

1723P_PR

Therapeutic nihilism or therapeutic realism: Perceptions of non-oncologist physicians regarding cancer patients’ prognosis

Abstract: Monday, 13 September 2021, 00:05 CEST

Full data set: Thursday, 16 September 2021, 08:30 CEST

1510MO_PR

European cancer patients’ perspectives on Immunotherapy

Abstract: Friday, 17 September 2021, 00:05 CEST

Full data set: Saturday, 18 September 2021, 17:30 CEST

1669O_PR

Late effects, long-term problems and unmet needs of cancer survivors

Abstract: Saturday, 18 September 2021, 00:05 CEST

Full data set: Tuesday, 21 September 2021, 13:30 CEST

LBA2_PR

KEYNOTE-826: A randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer

Abstract: Saturday, 18 September 2021, 00:05 CEST

Full data set: Saturday, 18 September 2021, 15:05 CEST

LBA3_PR

Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial

Abstract: Saturday, 18 September 2021, 00:05 CEST

Full data set: Saturday, 18 September 2021, 15:05 CEST

LBA4_PR

Abiraterone acetate and prednisolone (AAP) or AAP and enzalutamide (enza) added to androgen deprivation therapy (ADT) for men with high-risk locally advanced prostate cancer (PCa): metastases-free survival (MFS) results from STAMPEDE (NCT00268476)

Abstract: Saturday, 18 September 2021, 00:05 CEST

Full data set: Sunday, 19 September 2021, 15:05 CEST

LBA5_PR

A phase 3 trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1

Abstract: Saturday, 18 September 2021, 00:05 CEST

Full data set: Sunday, 19 September 2021, 15:05 CEST

LBA17_PR

Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

Abstract: Saturday, 18 September 2021, 00:05 CEST

Full data set: Sunday, 19 September 2021, 13:30 CEST

567O_PR

FIrst International Randomized STudy in MAlignant Progressive Pheochromocytoma and Paraganliomas (FIRSTMAPPP): an academic double-blind trial investigating Sunitinib

Abstract: Saturday, 18 September 2021, 00:05 CEST

Full data set: Monday, 20 September 2021, 15:05 CEST

Abstracts with a specific release date

Abstract ID

Title

Embargo lift

119O

Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized Phase 3 trial

Abstract + full data set: Thursday, 9 September 2021, 14:00 CEST

LBA65

First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients with unresectable malignant pleural mesothelioma: 3-year update from CheckMate 743

Abstract + full data set: Thursday, 9 September 2021, 14:00 CEST

1757O

Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients

Abstract + full data set: Friday, 17 September 2021, 18:00 CEST

LBA13

Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. Trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial

Abstract: Friday, 17 September 2021, 00:05 CEST

Full data set: Friday, 17 September 2021, 18:00 CEST

LBA15

Primary outcomes of the multi-center multinational randomized phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice combination chemotherapy in patients with pretreated HER2-positive locally advanced or metastatic breast cancer

Abstract: Saturday, 18 September 2021, 00:05 CEST

Full data set: Saturday, 18 September 2021, 18:00 CEST

579MO

CheckMate 9KD cohort A2 final analysis: nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)

Abstract: Friday, 17 September 2021, 00:05 CEST

Full data set: Saturday, 18 September 2021, 18:00 CEST

1123O

Comprehensive Evaluation of Cell-Free DNA (cfDNA) Multi-Omics for Multi-Cancer Early Detection (MCED)

Abstract: Saturday, 18 September 2021, 00:05 CEST

Full data set: Saturday, 18 September 2021, 18:00 CEST

Third-party media activities

Media activities initiated by third parties during or in connection with the event are subject to the ESMO Policy on Third-Party Media Activities which aims to guarantee proper and correct distribution of oncology and cancer-related information to media representatives in connection with the conference. Such media activities include (but are not limited to):

  • Meetings such as press conferences, media briefings and educational sessions involving media representatives
  • PR activities, such as press releases, news, articles, interviews, etc.

Press events concomitant with/or during breaks of the scientific programme of the event are subject to ESMO Press Office approval.

Please submit your request by contacting the ESMO Press Office at media@esmo.org.

Blackout times

During Blackout times any media event initiated by third parties is not allowed.

Friday, 17 September 2021

from 12:15 to 18:30 CEST

Saturday, 18 September 2021 

from 12:45 to 18:30  CEST

Sunday, 19 September 2021 

from 12:45 to 18:30  CEST 

Monday, 20 September 2021 

from 12:45 to 18:30  CEST

Tuesday, 21 September 2021 

from 12:45 to 17:30  CEST 

Wednesday, 22 September 2021 

from 13:00 to 18:25 CEST 

Contact

ESMO Press Office
E-mail: media@esmo.org

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings